Nkarta (NKTX) Treasury Shares (2022 - 2026)
Nkarta's quarterly Treasury Shares came in at $1.0 million in Q1 2026, up 17.71% year-on-year from $854884.0 in Q1 2025, and up 55.06% quarter-over-quarter from $648959.0 in Q4 2025.
Nkarta has reported Treasury Shares for 5 years, with the latest figure at $1.0 million in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares rose 17.71% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (up 17.71% YoY), and the FY2025 full-year result was $648959.0, down 44.43% from the prior year.
- Treasury Shares for Q1 2026 stood at $1.0 million, up from $648959.0 in the prior quarter.
- The five-year high for Treasury Shares was $1.2 million in Q1 2024, with the low at $229418.0 in Q1 2022.
- Average Treasury Shares over 5 years is $755077.1, with a median of $716956.0 recorded in 2023.
- Year-over-year, Treasury Shares soared 248.68% in 2023 and sank 44.43% in 2025.
- Tracing NKTX's Treasury Shares over 5 years: stood at $356728.0 in 2022, then soared by 66.73% to $594768.0 in 2023, then jumped by 96.36% to $1.2 million in 2024, then slumped by 44.43% to $648959.0 in 2025, then jumped by 55.06% to $1.0 million in 2026.
- The last three Treasury Shares figures came in at $1.0 million (Q1 2026), $648959.0 (Q4 2025), and $661636.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 265,401.92 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 700,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 34.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.01 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 648,959.00 |
| Dec 31, 2025 | 648,959.00 |
| Sep 30, 2025 | 661,636.00 |
| Sep 30, 2025 | 661,636.00 |
| Jun 30, 2025 | 832,299.00 |
| Jun 30, 2025 | 832,299.00 |
| Mar 31, 2025 | 854,884.00 |
| Mar 31, 2025 | 854,884.00 |
| Dec 31, 2024 | 1.17 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 594,768.00 |
| Dec 31, 2023 | 594,768.00 |
| Sep 30, 2023 | 695,110.00 |
| Sep 30, 2023 | 695,110.00 |
| Jun 30, 2023 | 716,956.00 |
| Jun 30, 2023 | 716,956.00 |
| Mar 31, 2023 | 799,930.00 |
| Mar 31, 2023 | 799,930.00 |
| Dec 31, 2022 | 356,728.00 |
| Dec 31, 2022 | 356,728.00 |
| Sep 30, 2022 | 359,708.00 |
| Sep 30, 2022 | 359,708.00 |
| Jun 30, 2022 | 320,278.00 |
| Jun 30, 2022 | 320,278.00 |
| Mar 31, 2022 | 229,418.00 |
| Mar 31, 2022 | 229,418.00 |